http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Cheolwon Suh,Sang Hee Kim,Hyo Jung Kim,Geundoo Jang,Eun Kyung Kim,Ok Bae Ko,Shin Kim,Hee Jung Sohn,Jung Shin Lee,Wookun Kim,Jooryung Huh 대한암학회 2005 Cancer Research and Treatment Vol.37 No.5
Purpose: Autologous stem cell transplantation (ASCT) is increasingly used in patients with non-Hodgkin’s lymphoma (NHL). Various clinical parameters-wereevaluated to obtain significant predictors of the outcome following ASCT in patients with NHLMaterials and Methods: Between April 1994 and December 2003, ASCT was performed on 80 patients with NHL at the Asan Medical Center. Results: Patients had various histological subtypes and disease status. The two year progression free survival (PFS) and overall survival for all patients were 34 and 31%, respectively. A univariate analysis showed the performance status, stage, modified extranodal involvement category, International Prognostic Index (IPI) at mobilization, disease status at mobilization, and history of radiation prior to mobilization as significant predictors of the outcome following ASCT. Four risk groups, with different 2 year PFS, were identified by the age adjusted IPI at mobilization (mAAIPI): low risk 44%; low intermediate risk 40%; high intermediate risk 19%; and high risk 0% (p=.0003). A multivariate analysis revealed 3 significant factors for the PFS: disease status, prior RT and mAAIPI. Conclusion: The mAAIPI was found to be an independent predictor of the outcome of NHL patients undergoing ASCT. This powerful prognostic tool should be used to evaluate potential candidates for ASCT.
제대혈의 적혈구 제거 방법에 관한 연구 : 제대혈 은행 설립을 위한 기초 연구 Basic Study for the Establishment of Cord Blood Bank
김효정,서철원,김상희,김상위,김성배,김강욱,조화정,민영주,박진희,김암,이인식,이필량,지현숙,서종진,강위창,이정신,김우건 대한조혈모세포이식학회 2000 대한조혈모세포이식학회지 Vol.5 No.1
배경:제대혈에서 적혈구를 제거하는 것은 제대혈 은행의 효율적인 운영 및 제대혈이식시 ABO 부적합 수혈, DMSO 독성 등의 부작용을 해결하기 위한 이상적인 방법이다. 저자들은 동일한 제대혈로 여러가지 적혈구 제거법을 동시에 시행하여, 이들에서 CD34양성 세포의 수득률 및 조혈세포 집락형성능을 비교하여 제대혈 은행 설립의 기반 기술을 확립하고자 하였다. 방법:제왕절개 직후 헤파린 처리된 용기에 제대혈을 채취하였다. 제대혈은 5개의 용기에 분산하여 실온에서 보관하였고 12시간 이내에 적혈구를 분리하였다. 적혈구 제거 방법으로 Ficoll 비중 분리법, gelatin 침전법, 적혈구 용혈법, starch 침전법을 각각의 제대혈에서 시행하였다. 전혈과 적혈구가 제거된 제대혈에서의 세포 생존율, 적혈구 제거율과 단핵구 및 CD34양성 세포의 수득률, 조혈세포 집락형성능을 비교 분석하였다. 결과:18례에서의 평균 제대혈 채취양은 81.3 mL(범위 42~128 mL)이었다. 서로 다른 적혈구 제거법들간에 세포 생존률과 적혈구 제거율은 차이가 없었다. 단핵구 수득률은 3% gelatin침전법(47.7±14.5%)이 다른 적혈구 제거법보다 유의하게 높았다. 3% gelatin침전법은 Ficoll비중 분리법과 Starch침전법에 비해 CD34 양성 세포수가 통계적으로 유의하게 높았다(36.1±5.4×10³/mL, 15.0±3.5×10³/mL, 20.7±4.2×10³/mL). 또한 CFC의 집락수도 3% gelatin침전법에서 Ficoll 비중 분리법과 적혈구 용혈법에 비해 우수한 결과를 보였다(52.0±7.1×10²/mL, 32.8±4.7×10²/mL, 36.8±5.7×10²/mL). 그러나 제대혈 전혈의 CD34 양성 세포수(65.7±11.2×10³/mL) 및 CFC의 집락수(117.8±15.8×10²/mL)를 적혈구 제거법을 이용한 실험군과 비교하였을 때 전혈군에서 높은 것을 알 수 있었다. 결론:3% gelatin 침전법은 다른 적혈구 제거법과 비교해 볼 때 더 우수한 단핵구, CD34 양성 세포 수득률 및 조혈세포 집락형성능을 보였다. 그러나 다른 보고들과는 달리 3% gelatin 침전법은 CD34양성 세포 및 CFC 집락수의 절대값이 제대혈 전혈과 비교하여 의미있게 낮았다. 이러한 결과는 시약의 종류와 실험방법의 차이에 기인하는 것으로 사료되며, 최상의 세포 수득률을 얻기 위하여 적혈구 분리 방법의 표준화를 위한 연구가 진행되어야 할 것으로 생각된다. Background:Efficient volume reduction is important to make a cost-effective umbilical cord blood (UCB) banking system. The aim of this study was to find a method of red cell depletion of UCB without major losses of the hematopoietic progenitor-CD34+ cells. Methods:Eighteen cord blood samples were collected in heparinized bottle immediately after Cesarean section. Five aliquots of each cord blood were stored at room temperature and processed within 12 hours. We used 4 different RBC depletion methods (Ficoll density gradient separation, gelatin sedimentation, red cell lysis, starch sedimentation) and compared the results of viability, RBC reduction rate, mononuclear cell (MNC) recovery rate, CD34+ cells and colony forming unit (CFC).Results: The mean collected cord blood volume was 81.3 mL (range 42~128 mL). There were no differences of viability and RBC reduction rate among groups. MNC recovery rate were significantly higher in gelatin group (47.7±14.5%) than other RBC depletion methods. Gelatin group had significantly higher CD34+ cell count than Ficoll and starch group (36.1±5.4×10³/mL, 15.0±3.5×10³/mL, 20.7±4.2×10³/mL) and higher CFC count than Ficoll and RBC lysis group (52.0±7.1×10²/mL, 32.8±4.7×10²/mL, 36.8±5.7×10²/mL). But the results of CD34+ cell count (65.7±11.2×10³/mL) and CFC count (117.8±15.8×10²/mL) of untreated control group are significantly higher than those of all other treated groups. Conclusion:Umbilical cord blood processed with 3% gelatin sedimentation has higher recovery rate of MNC, CD34+, cell and CFC than other groups. Unlike other reports, the absolute numbers of CD34+ cell and CFC count of 3% gelatin sedimentation method are significantly lower than those of untreated control group. Different laboratory processes with gelatin could be one cause of these differences, a study for standardized laboratory methods should be established to obtain higher recovery rate of hematopoietic cells after RBC depletion.
VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.
Kim, Min Kyoung,Suh, Cheolwon,Chi, Hyun Sook,Cho, Hee Soon,Bae, Young Kyung,Lee, Kyung Hee,Lee, Gyeong-Won,Kim, In-Suk,Eom, Hyeon-Seok,Kong, Sun-Young,Bae, Sung Hwa,Ryoo, Hun Mo,Shin, Im-Hee,Mun, Yeun Japanese Cancer Association 2012 Cancer Science Vol.103 No.3
<P>We evaluated the impact of functional polymorphisms in the vascular endothelial growth factor A (VEGFA) and vascular endothelial growth factor 2 (VEGFR2) genes on the survival of patients with diffuse large B cell lymphoma (DLBCL). Five potentially functional polymorphisms in the VEGFA (rs699947, rs2010963 and rs3025039) and VEGFR2 (rs1870377 and rs2305948) genes were assessed in 494 DLBCL patients treated with rituximab plus CHOP chemotherapy. The associations of genotype and haplotype with overall survival (OS) and progression-free survival (PFS) were analyzed. Of the five polymorphisms, VEGFR2 rs1870377T>A was significantly associated with both OS and PFS; in the dominant model, patients with the AA + TA genotypes had significantly better OS (P = 0.002) and PFS (P = 0.004) than those with the TT genotype. The association between significantly better OS and the AA + TA genotypes was observed separately in patients with low (0-2; P = 0.035) and high (3-5; P = 0.043) International Prognostic Index scores. Multivariate analysis showed that, relative to the AA + TA genotypes, the TT genotype was an independent prognostic factor for poor OS (HR, 1.71; 95% CI, 1.21-2.43; P = 0.002) and PFS (HR, 1.57; 1.13-2.17; P = 0.004). Other independent significant predictors of survival in patients with DLBCL were International Prognostic Index score, age > 60 years, lactate dehydrogenase concentration >normal, extranodal disease >1 and presence of B symptoms. The VEGFR2 rs1870377 polymorphism might affect survival in patients with DLBCL, suggesting that angiogenesis might be related to poor survival in these patients.</P>
Se-Hoon Lee,Keunchil Park,Cheolwon Suh,Hoon-Kyo Kim,Jun-Suk Kim,Young-Hyuc Kim,Sang-We Kim,Dae-Seog Heo,Yung-Jue Bang,Noe Kyeong Kim 대한암학회 2003 Cancer Research and Treatment Vol.35 No.1
Purpose: A combination of paclitaxel and cisplatin isan effective and safe regimen for advanced non-small celllung cancer (NSCLC). We conducted a multi-center,phase II trial to evaluate the efficacy and safety ofGenexol (paclitaxel) and cisplatin in patients withNSCLC.Materials and Methods: Chemotherapy-naïve patientshaving histologically confirmed NSCLC were enrolled.Genexol was administered at 175 mg/m2 as a 3-hourintravenous infusion and cisplatin at 75 mg/m2 as anintravenous infusion on day 1 every 3 weeks.Results: Twenty-five of 27 patients that were enteredfrom 5 hospitals between Jan 2001 and Aug 2001 receivedchemotherapy. On an intent-to-treat basis, 9 patients(36%) achieved a partial response, 7 patients (28%) astable disease, and 5 patients (20%) progressed. Theoverall response rate was 36% (95% CI, 17 to 55%). Themedian duration of the response was 7.8 months (95%CI, 6.6 to 9.0 months). The median time to progressionwas 7.4 months (95% CI, 5.3 to 9.5 months), and medianoverall survival was 13.3 months (95% CI, 10.8 to 15.9months) for the intent-to-treat population. The major toxicitywas hematological, with grade 3 and 4 neutropeniain 10% (10/106) of the total cycles. The non-hematologictoxicity was mild, and grade 3 emesis was observed in2 patients (8%). One patient experienced a moderatedegree hypersensitivity reaction.Conclusion: The results suggest that a combination ofGenexol and cisplatin is an effective and well-toleratedregimen for patients with NSCLC. (Cancer Res Treat. 2003;35:30-34)